(PTCT) PTC Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.126m USD | Total Return: 39.7% in 12m
Avg Turnover: 68.7M
Qual. Beats: 0
Rev. Trend: 59.2%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Interest Coverage Ratio -0.4 is critical
Altman Z'' -0.56 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Confidence
PTC Therapeutics (PTCT) is a biopharmaceutical firm specializing in rare disorders, with a portfolio targeting Duchenne muscular dystrophy, spinal muscular atrophy, and AADC deficiency. The company utilizes a hybrid commercial model, combining internal drug discovery with strategic licensing and third-party distribution networks. Its development pipeline leverages gene therapy and splicing platforms to address neurological and metabolic conditions like Huntington’s disease and phenylketonuria.
The biotechnology sector is characterized by high research and development intensity, where companies often rely on milestone payments and royalty streams from large-cap partners like Roche and Novartis. PTC’s business model focuses on orphan drug designations, which provide extended market exclusivity and specialized regulatory pathways for treating small patient populations. Investors may find it useful to examine ValueRay for further data on these clinical milestones.
- FDA approval of Kebilidi for AADC deficiency expands gene therapy revenue base
- Royalty revenue growth driven by global commercial uptake of SMA drug Evrysdi
- Phase 3 data for sepiapterin in PKU impacts long-term rare disease valuation
- Clinical milestones for Huntington’s disease candidate PTC518 dictate future pipeline stability
- Regulatory decisions regarding Translarna marketing authorization in Europe affect core DMD revenue
| Net Income: -186.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -27.68 > 1.0 |
| NWC/Revenue: 160.8% < 20% (prev 97.08%; Δ 63.77% < -1%) |
| CFO/TA -0.08 > 3% & CFO -217.9m > Net Income -186.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.5m) vs 12m ago -4.47% < -2% |
| Gross Margin: 77.84% > 18% (prev 96.87%; Δ -19.03% > 0.5%) |
| Asset Turnover: 29.94% > 50% (prev 66.76%; Δ -36.82% > 0%) |
| Interest Coverage Ratio: -0.41 > 6 (EBIT TTM -69.2m / Interest Expense TTM 167.2m) |
| A: 0.46 (Total Current Assets 2.25b - Total Current Liabilities 923.6m) / Total Assets 2.87b |
| B: -1.03 (Retained Earnings -2.97b / Total Assets 2.87b) |
| C: -0.03 (EBIT TTM -69.2m / Avg Total Assets 2.76b) |
| D: -0.06 (Book Value of Equity -180.5m / Total Liabilities 3.05b) |
| Altman-Z'' = -0.56 = B |
| DSRI: 2.24 (Receivables 219.9m/210.5m, Revenue 827.1m/1.77b) |
| GMI: 1.24 (GM 96.87% / 77.84%) |
| AQI: 2.02 (AQ_t 0.17 / AQ_t-1 0.08) |
| SGI: 0.47 (Revenue 827.1m / 1.77b) |
| TATA: 0.01 (NI -186.7m - CFO -217.9m) / TA 2.87b) |
| Beneish M = -1.56 (Cap -4..+1) = CCC |
As of June 03, 2026, the stock is trading at USD 68.23 with a total of 1,019,011 shares traded.
Over the past week, the price has changed by +0.86%,
over one month by +4.18%,
over three months by +2.80% and
over the past year by +39.73%.
PTC Therapeutics has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy PTCT.
- StrongBuy: 5
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 91.6 | 34.2% |
P/E Forward = 53.4759
P/S = 7.4063
P/B = 1743.2734
P/EG = 0.81
Revenue TTM = 827.1m USD
EBIT TTM = -69.2m USD
EBITDA TTM = -22.2m USD
Long Term Debt = 2.03b USD (from longTermDebt, last fiscal year)
Short Term Debt = 305.0m USD (from shortTermDebt, last quarter)
Debt = 2.44b USD (corrected: LT Debt 2.03b + ST Debt 305.0m) + Leases 108.2m
Net Debt = 2.22b USD (calculated: Debt 2.44b - CCE 214.6m)
Enterprise Value = 8.35b USD (6.13b + Debt 2.44b - CCE 214.6m)
Interest Coverage Ratio = -0.41 (Ebit TTM -69.2m / Interest Expense TTM 167.2m)
EV/FCF = -117.9x (Enterprise Value 8.35b / FCF TTM -70.8m)
FCF Yield = -0.85% (FCF TTM -70.8m / Enterprise Value 8.35b)
FCF Margin = -8.56% (FCF TTM -70.8m / Revenue TTM 827.1m)
Net Margin = -22.58% (Net Income TTM -186.7m / Revenue TTM 827.1m)
Gross Margin = 77.84% ((Revenue TTM 827.1m - Cost of Revenue TTM 183.3m) / Revenue TTM)
Gross Margin QoQ = 85.47% (prev 90.10%)
Tobins Q-Ratio = 2.91 (Enterprise Value 8.35b / Total Assets 2.87b)
Interest Expense / Debt = 6.86% (Interest Expense 167.2m / Debt 2.44b)
Taxrate = 2.01% (14.0m / 696.6m)
NOPAT = -67.8m (EBIT -69.2m * (1 - 2.01%)) [loss with tax shield]
Current Ratio = 2.37 (Total Current Assets 2.25b / Total Current Liabilities 949.1m)
Debt / Equity = -13.51 (negative equity) (Debt 2.44b / totalStockholderEquity, last quarter -180.5m)
Debt / EBITDA = -100.3 (out of range, set to none) (Net Debt 2.22b / EBITDA -22.2m)
Debt / FCF = -31.40 (negative FCF - burning cash) (Net Debt 2.22b / FCF TTM -70.8m)
Total Stockholder Equity = -187.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.76% (Net Income -186.7m / Total Assets 2.87b)
RoE = 99.84% (negative equity) (Net Income TTM -186.7m / Total Stockholder Equity -187.0m)
RoCE = -3.76% (EBIT -69.2m / Capital Employed (Equity -187.0m + L.T.Debt 2.03b))
RoIC = -3.07% (negative operating profit) (NOPAT -67.8m / Invested Capital 2.21b)
WACC = 7.90% (E(6.13b)/V(8.56b) * Re(8.37%) + D(2.44b)/V(8.56b) * Rd(6.86%) * (1-Tc(0.02)))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.21 | Cagr: 4.61%
[DCF] Fair Price = unknown (Cash Flow -70.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.12 | # QB: 0
Revenue Correlation: 59.23 | Revenue CAGR: 26.31% | SUE: 0.16 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=+172.46% | Revisions=N/A | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.47 | Chg30d=+191.02% | Revisions=N/A | Analysts=3
EPS current Year (2026-12-31): EPS=1.31 | Chg30d=+166.66% | Revisions=N/A | GrowthEPS=-82.8% | GrowthRev=-32.9%
EPS next Year (2027-12-31): EPS=2.78 | Chg30d=+14.54% | Revisions=+20% | GrowthEPS=+111.9% | GrowthRev=+11.2%
[Analyst] Revisions Ratio: +20%